Matthew Hummel, MD
Family Medicine · Fountain Hills, AZNPI 1780644526
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $18,277 of the $24,989 with a category attached, or 73.1%. 60 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 26.6% of the total. Reporting peaked in 2020 at $9,244 and has fallen 76.4% since, to $2,181 in 2025. Among family medicine clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,081 payments — averaging $23.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$7K
- AstraZeneca$3K
- AbbVie$2K
- Amgen$2K
- Lilly USA, LLC$1K
- GSK$852
- plus $9K from 54 others
Across 39 payments — averaging $2119.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$43K
- AbbVie$28K
- Pfizer$8K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Eli Lilly$1K
- Shionogi Inc$600
- plus $212 from 1 others
What the payments were for
- Grants$3,31913%
- Food & beverage$18,27773%
- Education$3,39314%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,989 in reported general payments places this provider in the 95th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 171 | $216,970 |
| Repatha SureclickEvolocumab | 136 | $160,980 |
| EliquisApixaban | 95 | $137,986 |
| MounjaroTirzepatide | 115 | $133,759 |
| OzempicSemaglutide | 72 | $85,719 |
| TrulicityDulaglutide | 31 | $53,192 |
| GemtesaVibegron | 40 | $51,170 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $50,624 |
| MyrbetriqMirabegron | 34 | $42,768 |
| JanuviaSitagliptin Phosphate | 27 | $40,711 |
| XareltoRivaroxaban | 27 | $35,314 |
| Praluent PenAlirocumab | 25 | $35,006 |
| VraylarCariprazine Hcl | 14 | $33,847 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $21,873 |
| LinzessLinaclotide | 17 | $21,258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $3,015 | $236,524192 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,037 | $186,951146 claims |
| PfizerEliquis | $829 | $137,98695 claims |
| Novo NordiskOzempic | $610 | $85,71972 claims |
| AbbVieVraylar, Linzess, Synthroid | $2,378 | $63,234115 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $852 | $60,15650 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $328 | $51,17040 claims |
| Johnson & JohnsonXarelto, Invokana | $312 | $43,83439 claims |
| Astellas Pharma US IncMyrbetriq | $179 | $42,76834 claims |
| MerckJanuvia | $63 | $40,71127 claims |
| Antares Pharma, Inc.Xyosted | $567 | $19,48932 claims |
| NovartisEntresto | $403 | $18,08818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Fountain Hills
- Douglas CunninghamPhoenix$1.8M
- Mitchell EdelsteinPhoenix$741K
- Lorena Jauregui-CovarrubiasYuma$491K
- Sam FereidouniScottsdale$486K
- Jessica BlancoChandler$447K
- Heather ElwoodPhoenix$236K
- Ryan CaseyYuma$231K
- Suzanne BentzMesa$174K
- Brent AllanParadise Valley$108K
- Ahmed AghaPhoenix$92K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.